论文部分内容阅读
目的 研究拉咪呋啶在治疗乙型肝炎过程中乙型肝炎病毒基因突变与耐药的关系。方法 选择 1 4 9例服用拉咪呋啶用药 1年后 ,且 HBV DNA含量持续维持在较高水平或 DNA含量有反跳现象的乙型肝炎患者 ,留取服药前和服药 1年后的两份血清 ,分别作 YVDD、YIDD、HBV M的检测 ,同时设置 2 0例未服用拉咪呋啶乙型肝炎患者为对照组。结果 在实验组 1 4 9例中有 70 % YVDD或 YIDD阳性 ,对照组无 1例阳性。HBV M,在 1 4 9例中有 1 2 %发生了三种模式的转化。结论 乙型肝炎病毒 P基因 C区 YMDD的突变与耐拉咪呋啶有直接关系
Objective To study the relationship between hepatitis B virus (HBV) gene mutation and drug resistance during the treatment of hepatitis B in rabeprazide. Methods One hundred and ninety-nine patients with hepatitis B who took lamivudine for one year and HBV DNA content maintained at a high level or had a rebound in DNA content were enrolled in this study. Serum samples were separately tested for YVDD, YIDD and HBV M, and 20 patients who did not take lamivudine and hepatitis B were set as control group. Results There were 70% YVDD or YIDD positive cases in the experimental group and none in the control group. In HBV M, 12% of the 149 cases occurred in three modes of conversion. Conclusion The mutation of YMDD in C region of P gene of hepatitis B is directly related to resistance to